Oncopeptides: All eyes on Europe - Redeye

Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple myeloma. Securing growth capital through a fully guaranteed rights issue, the company now stands financed to continue its European launch, which has demonstrated good momentum so far. At current levels, we identify upside in the share as we believe the growth trajectory is not reflected in the share price.

Länk till analysen i sin helhet: https://www.redeye.se/research/997273/all-eyes-on-europe?utm_source=finwire&utm_medium=RSS